▲ 3.21%
prev close
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-01-31 | ARWRArrowhead Pharmaceuticals, Inc. | Sell | $1,001 - $15,000 | 1195d ago | — |
2023-01-31
Daniel Goldman
ARWR
Amount
$1,001 - $15,000
Filed
1195d ago
Recent News
Powered by Polygon.io
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-01-31 · Sale
$1,001 - $15,000